A practical reference on AOD-9604: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-11-13. Anything still debated is marked as such rather than presented as settled.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
=== Biomimetic compounds === Our understanding of the mechanism of galactose oxidase inspires researchers to develop model compounds that mimics the structure and function of galactose oxidase. It appears that electron-sharing between the copper and the free radical is the crucial element in the success of synthesizing these compounds. The first model compound of GAOX made is [Cu(II)(dnc)], which utilizes duncamine (dnc) as the chelating ligand. Other model compounds have been studied and reported in literature.
=== Impact of nucleation === Nucleation lays the foundation for the nanoparticle synthesis. Initial nuclei play a vital role on the size and shape of the nanoparticles that will ultimately form by acting as templating nuclei for the nanoparticle itself. Long-term stability is also determined by the initial nucleation procedures. Homogeneous nucleation occurs when nuclei form uniformly throughout the parent phase and is less common. Heterogeneous nucleation, however, forms on areas such as container surfaces, impurities, and other defects. Crystals can form simultaneously when nucleation occurs rapidly, resulting in a more uniform (monodisperse) product. In contrast, slow nucleation rates often lead to a diverse (polydisperse) population of crystals with varying sizes. This phenomenon is exemplified in the formation of CaCO3 crystals. Controlling nucleation allows for the control of size, dispersity, and phase of nanoparticles. The process of nucleation and growth within nanoparticles can be described by nucleation, Ostwald ripening or the two-step mechanism-autocatalysis model.
In 1511, Malacca was conquered by Portugal, after which it was taken by the Dutch in 1641. In 1786, the British Empire established a presence in Malaya, when the Sultan of Kedah leased Penang Island to the British East India Company. The British obtained the town of Singapore in 1819, and in 1824 took control of Malacca following the Anglo-Dutch Treaty. By 1826, the British directly controlled Penang, Malacca, Singapore, and the island of Labuan, which they established as the crown colony of the Straits Settlements. By the 20th century, the states of Pahang, Selangor, Perak, and Negeri Sembilan, known together as the Federated Malay States, had British residents appointed to advise the Malay rulers, to whom the rulers were bound to defer by treaty. The remaining five states on the peninsula, known as the Unfederated Malay States, while not directly under British rule, also accepted British advisers around the turn of the 20th century. Development on the peninsula and Borneo were generally separate until the 19th century. Under British rule the immigration of Chinese and Indians to serve as labourers was encouraged. The area that is now Sabah came under British control as North Borneo when both the Sultan of Brunei and the Sultan of Sulu transferred their respective territorial rights of ownership, between 1877 and 1878. In 1842, Sarawak was ceded by the Sultan of Brunei to James Brooke, whose successors ruled as the White Rajahs over an independent kingdom until 1946, when it became a crown colony.
=== Chemical industry === Stainless-steel belts are part of continuous production processes. Unlike conveyor belts used purely for transportation purposes, steel belts used in this industry serve as media for transferring heat and/or pressure. Applications for steel belts in the chemical industry include casting, polymerizing of resins, waxes, paraffins and many other substances.
Sources: en.wikipedia.org
The earliest study of endocrinology began in China. The Chinese were isolating sex and pituitary hormones from human urine and using them for medicinal purposes by 200 BC. They used many complex methods, such as sublimation of steroid hormones. Another method specified by Chinese texts—the earliest dating to 1110—specified the use of saponin (from the beans of Gleditsia sinensis) to extract hormones, but gypsum (containing calcium sulfate) was also known to have been used. Although most of the relevant tissues and endocrine glands had been identified by early anatomists, a more humoral approach to understanding biological function and disease was favoured by the ancient Greek and Roman thinkers such as Aristotle, Hippocrates, Lucretius, Celsus, and Galen, according to Freeman et al., and these theories held sway until the advent of germ theory, physiology, and organ basis of pathology in the 19th century. In 1849, Arnold Berthold noted that castrated cockerels did not develop combs and wattles or exhibit overtly male behaviour. He found that replacement of testes back into the abdominal cavity of the same bird or another castrated bird resulted in normal behavioural and morphological development, and he concluded (erroneously) that the testes secreted a substance that "conditioned" the blood that, in turn, acted on the body of the cockerel. In fact, one of two other things could have been true: that the testes modified or activated a constituent of the blood or that the testes removed an inhibitory factor from the blood.
=== The Nobel Prize in Chemistry 1944 === On 16 November 1945 the Royal Swedish Academy of Sciences announced that Hahn had been awarded the 1944 Nobel Prize in Chemistry "for his discovery of the fission of heavy atomic nuclei." Hahn was still at Farm Hall when the announcement was made; thus, his whereabouts were a secret, and it was impossible for the Nobel committee to send him a congratulatory telegram. Instead, he learned about his award on 18 November through the Daily Telegraph. His fellow interned scientists celebrated his award by giving speeches, making jokes, and composing songs. Hahn had been nominated for the chemistry and the physics Nobel prizes many times even before the discovery of nuclear fission. Several more followed for the discovery of fission. The Nobel prize nominations were vetted by committees of five, one for each award. Although Hahn and Meitner received nominations for physics, radioactivity and radioactive elements had traditionally been seen as the domain of chemistry, and so the Nobel Committee for Chemistry evaluated the nominations. The committee received reports from Theodor Svedberg and Arne Westgren. These chemists were impressed by Hahn's work, but felt that of Meitner and Frisch was not extraordinary, and did not understand why the physics community regarded their work as seminal. As for Strassmann, although his name was on the papers, there was a long-standing policy of conferring awards on the most senior scientist in a collaboration. The committee therefore recommended that Hahn alone be given the chemistry prize.
Michael Peter Epstein (born April 4, 1943), nicknamed "Super Jew", is an American former professional baseball player for the Baltimore Orioles, Washington Senators / Texas Rangers, Oakland Athletics, and California Angels of Major League Baseball (MLB).
Sources: en.wikipedia.org
A 58-hour curfew was announced in Kherson. Oleksandr Prokudin, the Ukrainian governor of Kherson Oblast, said that during the curfew: "it is forbidden to move on the streets of the city. The city will also be closed for entry and exit". Twenty-four civilians were killed in Kherson city due to Russian shelling. Russia said it had shot down two drones over the Moscow Kremlin and accused Ukraine of sending them to assassinate President Vladimir Putin. The Institute for the Study of War commented that it was "extremely unlikely that two drones could have penetrated multiple layers of air defence and detonated or been shot down just over the heart of the Kremlin in a way that provided spectacular imagery caught nicely on camera". The Ukrainian government denied the accusations, calling them fabricated. The British Ministry of Defence reported that several unmanned aerial vehicles (UAVs) struck Russia's Seshcha Airbase in Bryansk Oblast, 150 km north of the Ukrainian border, adding that an An-124 heavy transport aircraft was likely damaged.
GlcA = β-D-glucuronic acid, IdoA = α-L-iduronic acid, IdoA(2S) = 2-O-sulfo-α-L-iduronic acid, GlcNAc = 2-deoxy-2-acetamido-α-D-glucopyranosyl, GlcNS = 2-deoxy-2-sulfamido-α-D-glucopyranosyl, GlcNS(6S) = 2-deoxy-2-sulfamido-α-D-glucopyranosyl-6-O-sulfate One unit of heparin (the "Howell unit") is an amount approximately equivalent to 0.002 mg of pure heparin, which is the quantity required to keep 1 ml of cat's blood fluid for 24 hours at 0 °C.
Unit I – Bonthapally: The primary manufacturing hub situated in Bonthapally village, Medak District, Telangana, with multiple production blocks including kilo labs and quality assurance laboratories. It holds approvals from major regulatory agencies and supports commercial API production. Unit II – Pashamylaram: A large-scale manufacturing facility comprising multiple production blocks, an engineering workshop, and warehouses. Unit III – Gaddapotharam: A multi-product facility designed for advanced intermediates and APIs, with analytical development and pilot plant capabilities. R&D Centre – Bonthapally: Research and development centre with a team of approximately 360 scientists, pilot labs, and analytical capabilities to catalyze process development and technology transfer.
Naloxone is useful in treating both acute opioid overdose and respiratory or mental depression due to opioids. Whether it is useful in those in cardiac arrest due to an opioid overdose is unclear. It is included as a part of emergency overdose response kits distributed to heroin, fentanyl, and other opioid drug users, and to emergency responders. This has been shown to reduce rates of deaths due to overdose. A prescription for naloxone is recommended if a person is on a high dose of opioid (>100 mg of morphine equivalence/day), is prescribed any dose of opioid accompanied by a benzodiazepine, or is suspected or known to use opioids nonmedically. Prescribing naloxone should be accompanied by standard education that includes preventing, identifying, and responding to an overdose; rescue breathing; and calling emergency services. Distribution of naloxone to individuals likely to encounter people who overdose is one aspect of harm reduction strategies. However, with opioids that have longer half-lives, respiratory depression returns after naloxone has worn off; therefore, adequate dosing and continuous monitoring may be necessary.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.